Patients taking these drugs should contact their doctor immediately if they experience symptoms such as difficulty or discomfort in breathing and shortness of breath at rest or with little activity.
Health care providers should regularly monitor these patients for symptoms suggestive of interstitial lung disease (ILD) and/or pneumonia. If new or worsening respiratory symptoms are detected, treatment with CDK 4/6 inhibitors should be interrupted, and if severe ILD and/or pneumonia is present, treatment should be discontinued.
However, as the FDA noted, the overall benefits of using CDK 4/6 inhibitors as prescribed continue to outweigh the risks, as there is evidence that these drugs improve progression-free survival in patients.
The FDA MedWatch Safety Information and Adverse Event Reporting Program encourages patients and clinicians to report adverse events associated with CDK 4/6 inhibitor therapy.